◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › A › AQST

Aquestive Therapeutics Inc (AQST) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-26

Aquestive Therapeutics Inc (AQST) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Warren, United States with about 147 employees. Its market capitalization is roughly $487 million. In the fiscal year ended 2025-12-31, AQST reported $45M in revenue and ($84M) in net income.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Interactive charts & full statements → Open the AQST valuation workbench →

AQST Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312006-12-312005-12-31
Total Revenue$54M$45M$58M$51M$48M$51M$46M$53M$67M$67M$52M$3M$2M
Gross Profit$36M$27M$40M$30M$28M$36M$33M$32M$46M$47M$35M$1M$1M
Gross Margin %67.0%61.5%69.0%58.8%59.3%70.5%71.7%61.3%68.9%70.4%68.4%40.2%39.6%
Operating Income (EBIT)($53M)($70M)($31M)($15M)($42M)($35M)($43M)($53M)($49M)$0M($1M)($12M)($8M)
Operating Margin %-97.5%-156.4%-53.5%-29.9%-88.2%-68.2%-93.5%-100.1%-72.6%-0.2%-1.6%-449.2%-366.9%
Net Income($78M)($84M)($44M)($8M)($54M)($71M)($56M)($66M)($61M)($9M)($10M)($13M)($8M)
Net Margin %-144.6%-188.1%-76.7%-15.6%-114.1%-138.8%-121.7%-125.9%-91.0%-13.4%-18.5%-469.7%-390.2%
EBITDA($61M)($66M)($27M)$1M($40M)($45M)($39M)($54M)($50M)$3M$3M——

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AQST Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$14M$14M$13M$13M$10M$9M$12M$14M
Gross Profit$10M$11M$7M$8M$5M$5M$7M$9M
Gross Margin %70.9%76.0%55.2%64.8%54.4%58.1%61.9%67.2%
Operating Income (EBIT)($8M)($4M)($29M)($11M)($11M)($19M)($14M)($8M)
Operating Margin %-59.5%-29.1%-221.6%-89.6%-113.7%-222.1%-114.4%-61.2%
Net Income($23M)($8M)($32M)($15M)($14M)($23M)($17M)($12M)
Net Margin %-165.5%-55.8%-244.8%-120.6%-135.4%-263.0%-143.7%-85.0%
EBITDA($19M)($4M)($27M)($11M)($9M)($19M)($13M)($7M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AQST Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312006-12-312005-12-31
Cash from Operations (CFO)($45M)($52M)($36M)($6M)($10M)($33M)($45M)($60M)($13M)$6M($8M)($9M)($6M)
Capital Expenditures (CapEx)$1M$1M$0M$1M$3M$1M$1M$1M$2M$2M$1M$3M$3M
Free Cash Flow (FCF)($46M)($53M)($36M)($7M)($12M)($34M)($46M)($61M)($15M)$4M($9M)($13M)($9M)
FCF Margin %-85.0%-119.0%-62.4%-14.6%-25.8%-66.7%-100.3%-115.7%-22.0%5.6%-17.7%-465.3%-431.3%
Dividends Paid————$0M—$0M$3M—————

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AQST Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($9M)($15M)($8M)($13M)($8M)($23M)($6M)($12M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($10M)($15M)($9M)($13M)($8M)($24M)($7M)($12M)
FCF Margin %-69.8%-102.8%-65.7%-100.6%-80.2%-269.9%-54.8%-88.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AQST Balance Sheet History

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AQST viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

← AQNAll “A” companiesAQUA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.